vs

Side-by-side financial comparison of Invesco (IVZ) and SONOCO PRODUCTS CO (SON). Click either name above to swap in a different company.

Invesco is the larger business by last-quarter revenue ($1.7B vs $1.7B, roughly 1.0× SONOCO PRODUCTS CO). SONOCO PRODUCTS CO runs the higher net margin — 4.1% vs -58.9%, a 62.9% gap on every dollar of revenue. On growth, Invesco posted the faster year-over-year revenue change (6.2% vs -1.9%). Invesco produced more free cash flow last quarter ($432.2M vs $-428.3B). Over the past eight quarters, Invesco's revenue compounded faster (7.1% CAGR vs 1.2%).

Invesco Ltd. is an American independent investment management company headquartered in Atlanta, Georgia, with branch offices in 20 countries. Its common stock is a constituent of the S&P 500 and trades on the New York Stock Exchange. Invesco operates under the Invesco, Invesco Perpetual, and Powershares brand names.

Sonoco Products Company is an American provider of diversified consumer packaging, industrial products, protective packaging, and packaging supply chain services and the world's largest producer of composite cans, tubes, and cores. The company was founded in 1889 as Southern Novelty Company with annualized net sales of approximately $7.3 billion. Sonoco has 19,900 employees in more than 335 operations in 33 countries, serving more than 85 nations. The company is headquartered in Hartsville, S...

IVZ vs SON — Head-to-Head

Bigger by revenue
IVZ
IVZ
1.0× larger
IVZ
$1.7B
$1.7B
SON
Growing faster (revenue YoY)
IVZ
IVZ
+8.1% gap
IVZ
6.2%
-1.9%
SON
Higher net margin
SON
SON
62.9% more per $
SON
4.1%
-58.9%
IVZ
More free cash flow
IVZ
IVZ
$428.7B more FCF
IVZ
$432.2M
$-428.3B
SON
Faster 2-yr revenue CAGR
IVZ
IVZ
Annualised
IVZ
7.1%
1.2%
SON

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
IVZ
IVZ
SON
SON
Revenue
$1.7B
$1.7B
Net Profit
$-995.9M
$68.0M
Gross Margin
20.6%
Operating Margin
-86.2%
7.6%
Net Margin
-58.9%
4.1%
Revenue YoY
6.2%
-1.9%
Net Profit YoY
-575.8%
24.1%
EPS (diluted)
$-2.61
$0.68

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IVZ
IVZ
SON
SON
Q1 26
$1.7B
Q4 25
$1.7B
$1.8B
Q3 25
$1.6B
$2.1B
Q2 25
$1.5B
$1.9B
Q1 25
$1.5B
$1.7B
Q4 24
$1.6B
Q3 24
$1.5B
$1.7B
Q2 24
$1.5B
$1.6B
Net Profit
IVZ
IVZ
SON
SON
Q1 26
$68.0M
Q4 25
$-995.9M
$332.2M
Q3 25
$356.4M
$122.9M
Q2 25
$197.4M
$493.4M
Q1 25
$171.1M
$54.4M
Q4 24
$209.3M
Q3 24
$55.0M
$50.9M
Q2 24
$132.2M
$90.8M
Gross Margin
IVZ
IVZ
SON
SON
Q1 26
20.6%
Q4 25
19.6%
Q3 25
21.9%
Q2 25
21.3%
Q1 25
20.7%
Q4 24
Q3 24
21.4%
Q2 24
22.0%
Operating Margin
IVZ
IVZ
SON
SON
Q1 26
7.6%
Q4 25
-86.2%
29.4%
Q3 25
16.5%
9.1%
Q2 25
14.1%
9.2%
Q1 25
18.1%
7.4%
Q4 24
19.6%
Q3 24
6.6%
7.6%
Q2 24
13.9%
8.6%
Net Margin
IVZ
IVZ
SON
SON
Q1 26
4.1%
Q4 25
-58.9%
18.8%
Q3 25
21.7%
5.8%
Q2 25
13.0%
25.8%
Q1 25
11.2%
3.2%
Q4 24
13.1%
Q3 24
3.6%
3.0%
Q2 24
8.9%
5.6%
EPS (diluted)
IVZ
IVZ
SON
SON
Q1 26
$0.68
Q4 25
$-2.61
$3.33
Q3 25
$0.66
$1.23
Q2 25
$-0.03
$4.96
Q1 25
$0.38
$0.55
Q4 24
$0.46
Q3 24
$0.12
$0.51
Q2 24
$0.29
$0.92

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IVZ
IVZ
SON
SON
Cash + ST InvestmentsLiquidity on hand
$1.0B
$224.5M
Total DebtLower is stronger
$1.8B
$3.5B
Stockholders' EquityBook value
$12.2B
$3.6B
Total Assets
$27.1B
$11.1B
Debt / EquityLower = less leverage
0.15×
0.97×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IVZ
IVZ
SON
SON
Q1 26
$224.5M
Q4 25
$1.0B
$378.4M
Q3 25
$973.1M
$244.9M
Q2 25
$922.7M
$329.8M
Q1 25
$821.7M
$181.8M
Q4 24
$986.5M
Q3 24
$1.0B
$1.9B
Q2 24
$878.5M
$140.2M
Total Debt
IVZ
IVZ
SON
SON
Q1 26
$3.5B
Q4 25
$1.8B
$3.8B
Q3 25
$1.6B
$3.8B
Q2 25
$1.9B
$5.0B
Q1 25
$964.8M
$5.0B
Q4 24
$890.6M
Q3 24
$890.3M
$4.3B
Q2 24
$890.1M
$2.5B
Stockholders' Equity
IVZ
IVZ
SON
SON
Q1 26
$3.6B
Q4 25
$12.2B
$3.6B
Q3 25
$14.0B
$3.3B
Q2 25
$13.9B
$3.2B
Q1 25
$14.7B
$2.4B
Q4 24
$14.6B
Q3 24
$14.8B
$2.5B
Q2 24
$14.6B
$2.4B
Total Assets
IVZ
IVZ
SON
SON
Q1 26
$11.1B
Q4 25
$27.1B
$11.2B
Q3 25
$28.4B
$11.7B
Q2 25
$28.5B
$12.0B
Q1 25
$28.1B
$12.7B
Q4 24
$27.0B
Q3 24
$27.5B
$9.0B
Q2 24
$27.2B
$7.2B
Debt / Equity
IVZ
IVZ
SON
SON
Q1 26
0.97×
Q4 25
0.15×
1.05×
Q3 25
0.12×
1.15×
Q2 25
0.14×
1.54×
Q1 25
0.07×
2.03×
Q4 24
0.06×
Q3 24
0.06×
1.74×
Q2 24
0.06×
1.04×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IVZ
IVZ
SON
SON
Operating Cash FlowLast quarter
$455.8M
Free Cash FlowOCF − Capex
$432.2M
$-428.3B
FCF MarginFCF / Revenue
25.5%
-25554.2%
Capex IntensityCapex / Revenue
1.4%
3601.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$1.4B
$-427.6B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IVZ
IVZ
SON
SON
Q1 26
Q4 25
$455.8M
$412.9M
Q3 25
$606.2M
$291.5M
Q2 25
$547.9M
$193.4M
Q1 25
$-84.6M
$-208.1M
Q4 24
$316.9M
Q3 24
$438.4M
$162.1M
Q2 24
$489.1M
$109.3M
Free Cash Flow
IVZ
IVZ
SON
SON
Q1 26
$-428.3B
Q4 25
$432.2M
$322.3M
Q3 25
$586.4M
$225.6M
Q2 25
$530.4M
$98.6M
Q1 25
$-108.0M
$-300.8M
Q4 24
$309.9M
Q3 24
$410.0M
$70.5M
Q2 24
$462.4M
$16.0M
FCF Margin
IVZ
IVZ
SON
SON
Q1 26
-25554.2%
Q4 25
25.5%
18.2%
Q3 25
35.7%
10.6%
Q2 25
35.0%
5.2%
Q1 25
-7.1%
-17.6%
Q4 24
19.5%
Q3 24
27.1%
4.2%
Q2 24
31.2%
1.0%
Capex Intensity
IVZ
IVZ
SON
SON
Q1 26
3601.4%
Q4 25
1.4%
5.1%
Q3 25
1.2%
3.1%
Q2 25
1.2%
5.0%
Q1 25
1.5%
5.4%
Q4 24
0.4%
Q3 24
1.9%
5.5%
Q2 24
1.8%
5.7%
Cash Conversion
IVZ
IVZ
SON
SON
Q1 26
Q4 25
1.24×
Q3 25
1.70×
2.37×
Q2 25
2.78×
0.39×
Q1 25
-0.49×
-3.82×
Q4 24
1.51×
Q3 24
7.97×
3.18×
Q2 24
3.70×
1.20×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

IVZ
IVZ

Investment Advice$1.2B73%
Distribution And Shareholder Service$382.7M23%
Financial Service Other$51.0M3%
Investment Performance$28.9M2%

SON
SON

Consumer Packaging$1.1B65%
Industrial Paper Packaging$579.4M35%
All Other$55.1M3%

Related Comparisons